title: Biocompatibility of membranes used in the treatment of renal failure.
abstract: Haemodialysis membranes with a wide range of solute and hydraulic permeabilities are used clinically. Such membranes are manufactured from either cellulose or synthetic co-polymers and their biocompatibility is commonly characterized by the complement activation and white cell changes observed during their use. The cellobiosic unit may be modified by the partial or total replacement of the hydroxyl groups by diethylaminoethyl (Hemophan), acetate (cellulose acetate), triacetate (cellulose triacetate) or 2,5-acetate (Diaphan). We have undertaken a prospective study in which such renal membranes have been studied in terms of the complement activation and neutropenia produced with the aim of investigating the relationship between modification of the cellobiosic unit and the magnitude of neutropenia and complement activation, and the extent to which membrane base material influences these parameters, by comparing the changes observed in modified cellulose membranes with that for a synthetic membrane (polysulphone). Our findings show that, while the degree of substitution varies between < 1% and total substitution, there is no correlation between the numbers of hydroxyl groups replaced and alteration of complement activation and neutropenia. However, by modification of the cellobiosic unit it is possible to produce a membrane whose biocompatibility is similar to that of a membrane manufactured from a synthetic co-polymer such as polysulphone.
authors.affiliation: Department of Medicine, University of Newcastle upon Tyne, UK.
authors.forename: N A
authors.initials: NA
authors.lastname: Hoenich
authors.forename: C
authors.initials: C
authors.lastname: Woffindin
authors.forename: J N
authors.initials: JN
authors.lastname: Mathews
authors.forename: J
authors.initials: J
authors.lastname: Vienken
mesh_terms: D001672:Biocompatible Materials / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects; D002482:Cellulose / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology; D003167:Complement Activation / Q000187:drug effects; D018592:Cross-Over Studies; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D007962:Leukocytes / Q000187:drug effects; D008567:Membranes, Artificial; D009503:Neutropenia / Q000139:chemically induced; D010976:Platelet Count / Q000187:drug effects; D011108:Polymers / Q000737:chemistry / Q000494:pharmacology; D011446:Prospective Studies; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000628:therapy*; D013450:Sulfones / Q000737:chemistry / Q000494:pharmacology
chemical_list: D001672:Biocompatible Materials; D008567:Membranes, Artificial; D011108:Polymers; D013450:Sulfones; C054645:Hemophan; C017662:polysulfone P 1700; C005062:acetylcellulose; D002482:Cellulose